Bausch Health Companies Inc at Goldman Sachs Leveraged Finance and Credit Conference Transcript

May 12, 2022 / 04:05PM GMT
Franklin Jarman - Goldman Sachs Group, Inc., Research Division - VP & Senior Analyst

Great. Thanks, everyone. We'll go ahead and get started with our next panel. I am very excited to be sitting here with Bausch Health management team. We've got the CFO, Tom Vadaketh, here to my left. And to his left, we have Will Woodfield, the Treasurer of the company. So thank you, guys, very much for joining us today.

Questions and Answers:

Franklin Jarman - Goldman Sachs Group, Inc., Research Division - VP & Senior Analyst

So maybe just to start out, there's obviously been a lot of focus and debate around the transaction and the separation of the Bausch + Lomb business from Bausch Pharma. And I think to just level set folks, I'd love to hear from you how you're thinking about the pro forma cash flow story for Bausch Health, to start, and then maybe we can go into some of the debates around some of the exogenous factors that could potentially impact the cash flow going forward.

Thomas G. Vadaketh - Bausch Health Companies Inc. -
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot